Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

Overview

The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.

Full Title of Study: “Efficacy and Safety of Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars. A Pilot Study.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2012

Interventions

  • Drug: Adapalene
    • Adapalene Gel 0.3%

Arms, Groups and Cohorts

  • Experimental: Differin 0.3%
    • Differin® 0.3% Gel Adapalene 0.3% Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • Global Scarring Severity
    • Time Frame: Week 24
    • Grade Level: Macular disease Mild disease Moderate disease Severe disease

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female subjects of any race, aged 18 to 50 years inclusive
  • Subjects with a past history of acne and with moderate to severe facial atrophic acne scars

Exclusion Criteria

  • Subjects with active inflammatory acne lesions
  • Subjects with hypertrophic acne scars

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Galderma
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Manisha J. Patel, MD, Principal Investigator, Johns Hopkins Medical Institut

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.